Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | CALCRL | Q16602 | 4/20 | 0.53 |
| ▸ | NTSR2 | O95665 | 6/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 6/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666030 | 0.94 | SLC6A2 (0.53) | SLC6A2CALCRLNTSR2NTSR1SORT1 | |
| SCHEMBL29465927 | 0.91 | SLC6A2 (0.62) | SLC6A2CALCRLNTSR2NTSR1SORT1 | |
| SCHEMBL30784958 | 0.89 | NTSR2 (0.59) | SLC6A2CALCRLNTSR2NTSR1SORT1 | |
| SCHEMBL29796613 | 0.88 | NTSR1 (0.60) | SLC6A2NTSR2NTSR1SORT1AGTR1 | |
| SCHEMBL29517484 | 0.88 | NTSR1 (0.60) | SLC6A2NTSR2NTSR1SORT1AGTR1 | |
| SCHEMBL29796500 | 0.88 | NTSR1 (0.60) | SLC6A2NTSR2NTSR1SORT1AGTR1 | |
| SCHEMBL31275903 | 0.85 | SLC6A2 (0.57) | SLC6A2CALCRLNTSR2NTSR1SORT1 | |
| SCHEMBL30784911 | 0.84 | BACE1 (0.55) | — | |
| SCHEMBL31064877 | 0.84 | OPRK1 (0.53) | SLC6A2NTSR2NTSR1SORT1ACE | |
| SCHEMBL31086923 | 0.83 | NTSR1 (0.60) | SLC6A2NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295748-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SPOREGEN LIMITED (GB) | 2025-09-25 | — | — | US | disclosed |
| US-20220280579-A1 | Formulations for Prevention or Reduction of C. Difficile Infections | SPOREGEN LIMITED (GB) | 2022-09-08 | — | — | US | disclosed |
| EP-4017265-A1 | FORMULATIONS FOR PREVENTION OR REDUCTION OF C. DIFFICILE INFECTIONS | SporeGen Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280579-A1 | Formulations for Prevention or Reduction of C. Difficile Infections | SI, FABP2, CRY1 | SLC6A2 4013/4885CALCRL 1515/4885NTSR2 1627/4885 |
| US-20250295748-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | TLR3, TLR5, IRF3 | SLC6A2 1911/4885CALCRL 2400/4885NTSR2 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.